[go: up one dir, main page]

MX2021012386A - Trispecific binding proteins, methods, and uses thereof. - Google Patents

Trispecific binding proteins, methods, and uses thereof.

Info

Publication number
MX2021012386A
MX2021012386A MX2021012386A MX2021012386A MX2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A MX 2021012386 A MX2021012386 A MX 2021012386A
Authority
MX
Mexico
Prior art keywords
binding
binding proteins
polypeptide
binds
proteins
Prior art date
Application number
MX2021012386A
Other languages
Spanish (es)
Inventor
Ronnie Wei
Huawei Qiu
Béatrice Cameron
Tarik Dabdoubi
Cendrine Lemoine
Joerg Birkenfeld
Zhi- Yong YANG
Gary J Nabel
Ling Xu
Lan Wu
Edward Seung
Catherine Prades
Joerg Regula
Zhen Xing
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021012386A publication Critical patent/MX2021012386A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Provided herein are trispecific and/or tri valent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CDS polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
MX2021012386A 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof. MX2021012386A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
MX2021012386A true MX2021012386A (en) 2022-01-18

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012386A MX2021012386A (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof.

Country Status (14)

Country Link
EP (1) EP3953388A1 (en)
JP (1) JP2022527994A (en)
KR (1) KR20210149141A (en)
CN (1) CN113950484A (en)
AU (1) AU2020272839A1 (en)
BR (1) BR112021019915A2 (en)
CA (1) CA3136821A1 (en)
CO (1) CO2021014918A2 (en)
IL (1) IL286929A (en)
MX (1) MX2021012386A (en)
PH (1) PH12021500041A1 (en)
SG (1) SG11202111012QA (en)
TW (1) TW202104261A (en)
WO (1) WO2020210392A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006558A2 (en) * 2018-10-09 2021-07-13 Sanofi anti-cd38, anti-cd28 and anti-cd3 trispecific binding proteins and methods of use for the treatment of viral infection
TW202104274A (en) * 2019-04-09 2021-02-01 法商賽諾菲公司 Trispecific and/or trivalent binding proteins for treatment of hiv infection
AU2023356326A1 (en) * 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2025027003A1 (en) 2023-07-31 2025-02-06 Sanofi Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
TWI622597B (en) * 2011-03-28 2018-05-01 賽諾菲公司 Dual variable region antibody binding protein with cross-binding domain orientation
DK3189132T3 (en) * 2014-09-04 2020-08-10 Stemcell Tech Inc Soluble antibody complexes for T cell or NK cell activation and expansion
EP3747905A1 (en) * 2014-11-20 2020-12-09 F. Hoffmann-La Roche AG Common light chains and methods of use
AU2015348595B2 (en) * 2014-11-20 2021-06-10 F. Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against FOLR1 and CD3
WO2016116626A1 (en) * 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX2017016169A (en) * 2015-06-17 2018-08-15 Genentech Inc Anti-her2 antibodies and methods of use.
EP3313437A1 (en) * 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
JP7169190B2 (en) 2015-10-25 2022-11-10 サノフイ Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection
AU2017248671B2 (en) 2016-04-13 2024-06-20 Sanofi Trispecific and/or trivalent binding proteins
JP2019532017A (en) * 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター Multiple bispecific binding domain constructs exhibiting different epitope binding for treating cancer
WO2018120842A1 (en) * 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 Bifunctional molecule and use thereof
CN111788225B (en) * 2017-10-10 2025-02-18 赛诺菲 Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
BR112021006558A2 (en) * 2018-10-09 2021-07-13 Sanofi anti-cd38, anti-cd28 and anti-cd3 trispecific binding proteins and methods of use for the treatment of viral infection

Also Published As

Publication number Publication date
IL286929A (en) 2021-10-31
AU2020272839A1 (en) 2021-12-02
TW202104261A (en) 2021-02-01
CO2021014918A2 (en) 2021-11-19
CA3136821A1 (en) 2020-10-15
BR112021019915A2 (en) 2021-12-07
JP2022527994A (en) 2022-06-07
KR20210149141A (en) 2021-12-08
SG11202111012QA (en) 2021-11-29
PH12021500041A1 (en) 2022-06-06
CN113950484A (en) 2022-01-18
WO2020210392A1 (en) 2020-10-15
EP3953388A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
WO2017180913A3 (en) Trispecific and/or trivalent binding proteins
MX2022014631A (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection.
PH12021500041A1 (en) Trispecific binding proteins, methods, and uses thereof
HRP20210041T1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2018134235A8 (en) Improved serum albumin binders
EP4442708A3 (en) Improved serum albumin binders
MX2022015847A (en) Cd123 binding proteins and related compositions and methods.
MY164906A (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
EA202090718A1 (en) PROTEINS BINDING NKG2D, CD16 AND LECTIN-LIKE C-TYPE MOLECULE-1 (CLL-1)
WO2016130898A3 (en) Antibody therapeutics that bind ctla4
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
MX2021006362A (en) Single domain antibodies against cll-1.
PH12022551231A1 (en) Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
PH12021552148A1 (en) Cd3 binding molecules
EP4257193A3 (en) Trispecific and/or trivalent binding proteins
EP4269433A3 (en) Tgf-beta-rii binding proteins
PH12021500042A1 (en) Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA202191078A2 (en) TRISSPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION
NZ748144B2 (en) Trispecific and/or trivalent binding proteins
ATE492564T1 (en) EPHB4-BINDING ANTIBODIES FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
WO2023038803A3 (en) Engineered anti-her2 bispecific proteins
NZ727772B2 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof